NASDAQ · SINT
Healthcare · Medical - Devices
$1.64
Down-$0.10 (-5.75%)
Updated Oct 23, 2026, 7:28 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SINT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
SINT closed at $1.64 after 21 trading sessions, down 12.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $1.6501 | $1.8199 | $1.64 | $1.64 | 9.01K |
| Oct 21, 2026 | $1.6989 | $1.78 | $1.6989 | $1.74 | 20.2K |
| Oct 20, 2026 | $1.70 | $1.7296 | $1.6672 | $1.72 | 3.5K |
| Oct 19, 2026 | $1.71 | $1.7352 | $1.6592 | $1.70 | 22.26K |
| Oct 16, 2026 | $1.77 | $1.78 | $1.69 | $1.74 | 43.71K |
| Oct 15, 2026 | $1.80 | $1.84 | $1.73 | $1.77 | 15.93K |
| Oct 14, 2026 | $2.03 | $2.03 | $1.82 | $1.82 | 113.57K |
| Oct 13, 2026 | $2.14 | $2.21 | $2.05 | $2.07 | 36.89K |
| Oct 12, 2026 | $2.08 | $2.14 | $2.08 | $2.13 | 47.19K |
| Oct 9, 2026 | $2.12 | $2.18 | $2.05 | $2.11 | 140.6K |
| Oct 8, 2026 | $2.12 | $2.16 | $2.0704 | $2.11 | 29.21K |
| Oct 7, 2026 | $2.12 | $2.20 | $2.0501 | $2.17 | 40.89K |
| Oct 6, 2026 | $2.19 | $2.24 | $2.1215 | $2.18 | 50.53K |
| Oct 5, 2026 | $2.28 | $2.3378 | $2.17 | $2.18 | 118.26K |
| Oct 2, 2026 | $2.15 | $2.2956 | $2.12 | $2.21 | 158.15K |
| Oct 1, 2026 | $2.31 | $2.39 | $1.99 | $2.13 | 678.28K |
| Sep 30, 2026 | $2.04 | $2.30 | $2.02 | $2.23 | 79.44K |
| Sep 29, 2026 | $2.00 | $2.07 | $1.98 | $2.03 | 30.23K |
| Sep 28, 2026 | $1.89 | $2.10 | $1.89 | $1.99 | 107.53K |
| Sep 25, 2026 | $1.91 | $2.00 | $1.86 | $1.88 | 89.16K |
| Sep 24, 2026 | $1.75 | $1.91 | $1.7443 | $1.87 | 46.74K |
The latest Smart Investors Daily articles mentioning SINT.
Company
Market Activity
Research & News
SINT research
Company profile and research snapshot.
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Ascendiant Capital | Buy | — |
| Jun 4, 2026 | Maxim Group | Buy | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 13, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 14, 2026
SINTX Technologies (NASDAQ:SINT) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Yahoo · Oct 8, 2026
SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Oct 1, 2026
Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited reve
Benzinga · Oct 1, 2026
Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SINT.
